LRRC37A2

Summary

LRRC37A2 (leucine rich repeat containing 37 member A2, HGNC:32404) is a protein-coding gene on chromosome 17q21.31, encoding Leucine-rich repeat-containing protein 37A2 (A6NM11). It is a selective cancer dependency (DepMap: 35.7% of cell lines).

Predicted to enable ATP binding activity; ATP hydrolysis activity; and metal ion binding activity. Predicted to be involved in SNARE complex disassembly and protein transport. Predicted to be located in cytoplasm and membrane.

Source: NCBI Gene 474170 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 364 total — 3 pathogenic, 7 likely-pathogenic
• Phenotypes (HPO): 2
• Cancer dependency (DepMap): dependent in 35.7% of screened cell lines
• MANE Select transcript: NM_001006607

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32404
Approved symbol	LRRC37A2
Name	leucine rich repeat containing 37 member A2
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	FLJ45049
Ensembl gene	ENSG00000238083
Ensembl biotype	protein_coding
OMIM	616556
Entrez	474170

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 retained_intron, 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000572638, ENST00000576629, ENST00000705813, ENST00000706058, ENST00000706059, ENST00000706060, ENST00000706061, ENST00000706062, ENST00000706063, ENST00000706064, ENST00000706065, ENST00000706066

RefSeq mRNA: 2 — MANE Select: NM_001006607 NM_001006607, NM_001385803

CCDS: CCDS42353

Canonical transcript exons

ENST00000576629 — 14 exons

Exon	Start	End
ENSE00002345964	46523804	46523884
ENSE00002351239	46523084	46523155
ENSE00002353584	46548312	46549843
ENSE00002382963	46540176	46540247
ENSE00002410194	46540807	46540881
ENSE00002412179	46520212	46520283
ENSE00002646218	46512468	46515321
ENSE00003547431	46555285	46555424
ENSE00003672613	46553400	46553449
ENSE00003677727	46550415	46550519
ENSE00003693115	46555152	46555206
ENSE00003994204	46546255	46546373
ENSE00003994205	46517362	46517433
ENSE00003994206	46555531	46555646

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 94.93.

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	94.93	gold quality
right testis	UBERON:0004534	88.87	gold quality
cerebellar hemisphere	UBERON:0002245	88.31	gold quality
cerebellar cortex	UBERON:0002129	88.23	gold quality
cerebellum	UBERON:0002037	88.12	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.94	gold quality
pituitary gland	UBERON:0000007	87.72	gold quality
granulocyte	CL:0000094	87.65	gold quality
left testis	UBERON:0004533	87.58	gold quality
sural nerve	UBERON:0015488	87.49	gold quality
right coronary artery	UBERON:0001625	87.38	gold quality
testis	UBERON:0000473	87.20	gold quality
adenohypophysis	UBERON:0002196	87.07	gold quality
bone marrow cell	CL:0002092	86.84	gold quality
fundus of stomach	UBERON:0001160	86.20	gold quality
blood	UBERON:0000178	86.11	gold quality
amygdala	UBERON:0001876	85.79	gold quality
nucleus accumbens	UBERON:0001882	85.73	gold quality
lower esophagus mucosa	UBERON:0035834	85.69	gold quality
temporal lobe	UBERON:0001871	85.65	gold quality
Ammon’s horn	UBERON:0001954	85.63	gold quality
skeletal muscle tissue	UBERON:0001134	85.39	gold quality
caudate nucleus	UBERON:0001873	85.32	gold quality
right frontal lobe	UBERON:0002810	85.28	gold quality
primary visual cortex	UBERON:0002436	85.26	gold quality
putamen	UBERON:0001874	85.15	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.00	gold quality
superior frontal gyrus	UBERON:0002661	84.95	gold quality
prostate gland	UBERON:0002367	84.93	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.92	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6058	no	840.73
E-ANND-3	no	2.22

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 35.7% of screened cell lines.

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lrrc37	ENSMUSG00000034239
mus_musculus	Lrrc37a	ENSMUSG00000078632
rattus_norvegicus	Lrrc37a	ENSRNOG00000042025
rattus_norvegicus	Prp2l1	ENSRNOG00000042833

Paralogs (3): LRRC37A (ENSG00000176681), LRRC37A3 (ENSG00000176809), LRRC37B (ENSG00000185158)

Protein

Protein identifiers

Leucine-rich repeat-containing protein 37A2 — A6NM11 (reviewed: A6NM11)

All UniProt accessions (3): A6NM11, A0A994J7H6, A0A994J7J8

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the LRRC37A family.

RefSeq proteins (2): NP_001006608, NP_001372732 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR015753	LRRC37	Family
IPR029423	LRRC37AB_C	Domain
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR032754	LRRC37_N	Domain

Pfam: PF13855, PF14914, PF15779

UniProt features (46 total): compositionally biased region 13, repeat 10, region of interest 9, sequence variant 4, sequence conflict 3, topological domain 2, glycosylation site 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A6NM11-F1	42.32	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 296, 1079

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 44 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, WANG_CLIM2_TARGETS_UP, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN, MIKKELSEN_MCV6_LCP_WITH_H3K27ME3, TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C, WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP, DCA_UP.V1_DN, STK33_SKM_UP, JAK2_DN.V1_DN, GSE11057_EFF_MEM_VS_CENT_MEM_CD4_TCELL_DN, GSE11864_UNTREATED_VS_CSF1_IFNG_IN_MAC_DN, GSE11864_CSF1_IFNG_VS_CSF1_PAM3CYS_IN_MAC_UP

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

584 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRC37A2	ARL17B	I3L3L1	728
LRRC37A2	ARL17A	Q8IVW1	720
LRRC37A2	KANSL1	Q7Z3B3	677
LRRC37A2	ARHGAP27	Q6ZUM4	542
LRRC37A2	NXPE3	Q969Y0	507
LRRC37A2	SPPL2C	Q8IUH8	471
LRRC37A2	CRHR1	P34998	447
LRRC37A2	ZNF404	Q494X3	446
LRRC37A2	FLACC1	Q96Q35	445
LRRC37A2	ATP6AP1L	Q52LC2	431
LRRC37A2	ZSWIM7	Q19AV6	419
LRRC37A2	DCAKD	Q8WVC6	403
LRRC37A2	PLEKHM1	Q9Y4G2	399
LRRC37A2	NPIPB9	F8W1W9	397
LRRC37A2	MAPT	P10636	395

IntAct

8 interactions, top by confidence:

A	B	Type	Score
GSK3A	LRRC37A2	psi-mi:“MI:0915”(physical association)	0.370
PDK1	LRRC37A2	psi-mi:“MI:0914”(association)	0.350
LRRC37A2	GAPDHS	psi-mi:“MI:0914”(association)	0.350
	LRRC37A2	psi-mi:“MI:0915”(physical association)	0.000
rbsC	LRRC37A2	psi-mi:“MI:0915”(physical association)	0.000
bgaB	LRRC37A2	psi-mi:“MI:0915”(physical association)	0.000
LRRC37A2		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): LRRC37A2 (Affinity Capture-RNA), LRRC37A2 (Two-hybrid), CORO1A (Affinity Capture-MS), DUPD1 (Affinity Capture-MS), NCS1 (Affinity Capture-MS), GAPDHS (Affinity Capture-MS), SRC (Affinity Capture-MS), LRRC37A2 (Affinity Capture-MS), LRRC37A2 (Affinity Capture-RNA)

ESM2 similar proteins: A0A1B0GUW6, A1EGX6, A6NM11, A6NMS7, A6QLF8, D3YU32, I3L273, J3KML8, O35930, O60309, Q08DY0, Q14242, Q2TBI7, Q32KG4, Q32L62, Q3MIW9, Q3TNW5, Q3V0E1, Q4R729, Q5VWK0, Q5VYM1, Q62170, Q659K0, Q68DN1, Q6AZ54, Q6MG22, Q6UXB8, Q6ZRG5, Q8BUE7, Q8K4E0, Q8N307, Q8N3K9, Q8TCU4, Q8WNU4, Q8WXI7, Q95JY5, Q96F05, Q96JA4, Q96M34, Q96M43

Diamond homologs: A6NM11, A6NMS7, O60309, Q49AS3, Q96QE4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

364 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	7
Uncertain significance	186
Likely benign	107
Benign	30

Top pathogenic / likely-pathogenic (10)

Variant ID	HGVS	Classification
1120201	NM_006178.4(NSF):c.1375G>A (p.Ala459Thr)	Pathogenic
13812	NM_030753.5(WNT3):c.247C>T (p.Gln83Ter)	Pathogenic
4538544	NM_006178.4(NSF):c.664G>A (p.Gly222Ser)	Pathogenic
1066226	NM_004287.5(GOSR2):c.204-1G>T	Likely pathogenic
1344866	NM_003396.3(WNT9B):c.949G>A (p.Gly317Arg)	Likely pathogenic
1344867	NM_003396.3(WNT9B):c.11dup (p.Pro5fs)	Likely pathogenic
1465855	NM_004287.5(GOSR2):c.95-1G>C	Likely pathogenic
189347	NM_030753.5(WNT3):c.271T>C (p.Cys91Arg)	Likely pathogenic
2434446	NM_006178.4(NSF):c.1688C>G (p.Pro563Arg)	Likely pathogenic
4531662	NM_006178.4(NSF):c.695G>A (p.Arg232Gln)	Likely pathogenic

SpliceAI

1718 predictions. Top by Δscore:

Variant	Effect	Δscore
17:46520284:G:GG	donor_gain	1.0000
17:46520288:G:GG	donor_gain	1.0000
17:46523156:G:GG	donor_gain	1.0000
17:46523882:GTT:G	donor_gain	1.0000
17:46540878:AACT:A	donor_gain	1.0000
17:46540879:ACT:A	donor_gain	1.0000
17:46540880:CT:C	donor_gain	1.0000
17:46540881:TGTAA:T	donor_loss	1.0000
17:46540882:G:C	donor_loss	1.0000
17:46540882:G:GG	donor_gain	1.0000
17:46540883:T:TC	donor_loss	1.0000
17:46546371:GTC:G	donor_gain	1.0000
17:46546374:G:GG	donor_gain	1.0000
17:46546408:T:G	donor_gain	1.0000
17:46546408:T:TG	donor_gain	1.0000
17:46553393:A:AG	acceptor_gain	1.0000
17:46553398:A:C	acceptor_loss	1.0000
17:46553399:GAT:G	acceptor_gain	1.0000
17:46553399:GATAT:G	acceptor_gain	1.0000
17:46555280:TCTA:T	acceptor_loss	1.0000
17:46555282:TAG:T	acceptor_loss	1.0000
17:46555283:A:AG	acceptor_gain	1.0000
17:46555283:AG:A	acceptor_gain	1.0000
17:46555283:AGGAT:A	acceptor_gain	1.0000
17:46555284:G:GG	acceptor_gain	1.0000
17:46555284:GG:G	acceptor_gain	1.0000
17:46555284:GGA:G	acceptor_gain	1.0000
17:46555284:GGAT:G	acceptor_gain	1.0000
17:46555284:GGATG:G	acceptor_gain	1.0000
17:46555417:GACCC:G	donor_gain	1.0000

AlphaMissense

11083 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:46517433:T:C	L894P	0.987
17:46520227:T:A	N899K	0.987
17:46520227:T:G	N899K	0.987
17:46523099:T:A	N923K	0.987
17:46523099:T:G	N923K	0.987
17:46523098:A:T	N923I	0.986
17:46523819:T:A	N947K	0.986
17:46523819:T:G	N947K	0.986
17:46520241:T:C	L904S	0.984
17:46520217:T:C	L896P	0.983
17:46520226:A:T	N899I	0.983
17:46517377:C:A	N875K	0.982
17:46517377:C:G	N875K	0.982
17:46520232:T:C	L901S	0.981
17:46517367:T:C	F872S	0.980
17:46523104:T:C	I925T	0.980
17:46523809:T:C	L944P	0.978
17:46540881:T:C	L1018P	0.978
17:46523104:T:A	I925K	0.976
17:46517405:T:A	W885R	0.975
17:46517405:T:C	W885R	0.975
17:46523097:A:T	N923Y	0.974
17:46523818:A:T	N947I	0.971
17:46515239:T:C	C843R	0.969
17:46517376:A:T	N875I	0.969
17:46540191:T:A	N974K	0.969
17:46540191:T:G	N974K	0.969
17:46515234:T:C	L841S	0.968
17:46515239:T:A	C843S	0.968
17:46515240:G:C	C843S	0.968

dbSNP variants (sampled 300 via entrez): RS1000011317 (17:46944119 C>T), RS1000012117 (17:46843449 ACT>A), RS1000013309 (17:46811720 C>T), RS1000016042 (17:46782504 G>A,T), RS1000017699 (17:46837221 G>A), RS1000019296 (17:46473134 GAAT>G), RS1000021652 (17:46934847 T>G), RS1000032920 (17:46553066 A>G), RS1000040171 (17:46533354 T>A,G), RS1000051927 (17:46863818 C>A), RS1000055307 (17:46917912 C>T), RS1000055879 (17:46890859 C>G), RS1000066812 (17:46825789 C>G,T), RS1000067832 (17:46851356 G>C), RS1000068419 (17:46956015 C>T)

Disease associations

OMIM: gene MIM:616556 | disease phenotypes: MIM:254800, MIM:619340, MIM:614018, MIM:273395, MIM:600057, MIM:620166, MIM:203800

GenCC curated gene-disease

Mondo (12): progressive myoclonus epilepsy (MONDO:0020074), developmental and epileptic encephalopathy 96 (MONDO:0023659), progressive myoclonic epilepsy type 6 (MONDO:0013526), chronic kidney disease (MONDO:0005300), renal hypoplasia (MONDO:0019637), renal dysplasia (MONDO:0019638), tetraamelia syndrome 1 (MONDO:0060764), bladder exstrophy-epispadias-cloacal exstrophy complex (MONDO:0700039), muscular dystrophy, congenital, with or without seizures (MONDO:0859336), muscular dystrophy (MONDO:0020121), Alstrom syndrome (MONDO:0008763), developmental and epileptic encephalopathy (MONDO:0100620)

Orphanet (9): Progressive myoclonic epilepsy type 1 (Orphanet:308), Progressive myoclonic epilepsy (Orphanet:98261), Progressive myoclonic epilepsy type 6 (Orphanet:280620), Renal hypoplasia (Orphanet:93101), Renal dysplasia (Orphanet:93108), Tetraamelia-multiple malformations syndrome (Orphanet:3301), Classic bladder exstrophy (Orphanet:93930), Muscular dystrophy (Orphanet:98473), Alström syndrome (Orphanet:64)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000089	Renal hypoplasia
HP:0000110	Renal dysplasia

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST006268_483	Reaction time	7.000000e-21
GCST006661_283	Male-pattern baldness	4.000000e-27
GCST007592_2	Handedness (Left-handed vs. non-left-handed)	1.000000e-09
GCST007594_2	Handedness (Right-handed vs. non-right-handed)	2.000000e-08
GCST010083_12	Hemoglobin levels	1.000000e-11
GCST010083_64	Hemoglobin levels	3.000000e-54
GCST010135_31	Oily fish consumption	5.000000e-09
GCST010140_21	Pork consumption	5.000000e-09
GCST010703_91	Brain morphology (MOSTest)	2.000000e-65
GCST010989_22	Body size at age 10	3.000000e-09
GCST011088_5	Orofacial clefts	7.000000e-07
GCST90002391_94	Mean corpuscular hemoglobin concentration	3.000000e-10
GCST90010427_24	Left–right brain asymmetry	8.000000e-15

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0008393	reaction time measurement
EFO:0009902	handedness
EFO:0004509	hemoglobin measurement
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0004528	mean corpuscular hemoglobin concentration

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D056769	Alstrom Syndrome	C10.500.300.099; C10.574.500.495.099; C10.668.829.800.300.099; C11.270.684.249; C16.131.077.245.063; C16.131.666.300.099; C16.320.184.063; C16.320.290.684.249; C16.320.400.375.099
D007676	Kidney Failure, Chronic	C12.050.351.968.419.780.750.500; C12.200.777.419.780.750.500; C12.950.419.780.750.500; C23.550.291.500.906.500
D009136	Muscular Dystrophies	C05.651.534.500; C10.668.491.175.500; C16.320.577
D020191	Myoclonic Epilepsies, Progressive	C10.228.140.490.375.130.650; C10.228.140.490.493.063.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs758391	GOSR2, LRRC37A2		0.00	0

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Cadmium	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Smoke	increases abundance, increases expression	1
Thimerosal	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00073710	PHASE4	COMPLETED	Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium
NCT00125593	PHASE4	COMPLETED	Study of Heart and Renal Protection
NCT00132431	PHASE4	COMPLETED	START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
NCT00155246	PHASE4	COMPLETED	Efficacy of Pentoxifylline on Chronic Kidney Disease
NCT00175149	PHASE4	TERMINATED	Active Vitamin D Effect on Left Ventricular Hypertrophy
NCT00184769	PHASE4	COMPLETED	Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
NCT00190580	PHASE4	COMPLETED	Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease
NCT00194961	PHASE4	TERMINATED	Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease
NCT00239642	PHASE4	COMPLETED	Safety and Efficacy of Iron Sucrose in Children
NCT00324571	PHASE4	COMPLETED	Dialysis Clinical Outcomes Revisited (DCOR) Trial
NCT00364884	PHASE4	UNKNOWN	Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease
NCT00368901	PHASE4	COMPLETED	STAAR-2 Clinical Study
NCT00369733	PHASE4	COMPLETED	STAAR-3 Clinical Study
NCT00369772	PHASE4	COMPLETED	STAAR-1 Clinical Study
NCT00379899	PHASE4	COMPLETED	ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
NCT00384618	PHASE4	TERMINATED	Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study
NCT00478543	PHASE4	COMPLETED	Loop Diuretics in Chronic Kidney Disease
NCT00632125	PHASE4	COMPLETED	Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.
NCT00644046	PHASE4	COMPLETED	Chronic Kidney Disease Prevention of An-Lo District, Keelung
NCT00719316	PHASE4	UNKNOWN	Aliskiren and Muscle Sympathetic Nerve Activity
NCT00725517	PHASE4	COMPLETED	Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange
NCT00741585	PHASE4	COMPLETED	Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
NCT00749736	PHASE4	COMPLETED	The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.
NCT00752102	PHASE4	COMPLETED	Vitamin D and Coronary Calcification Study
NCT00756145	PHASE4	COMPLETED	The Use of Low Molecular Weight Heparin in Hemodiafiltration
NCT00768638	PHASE4	COMPLETED	Study of Atorvastatin Dose Dependent Reduction of Proteinuria
NCT00786136	PHASE4	COMPLETED	Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes
NCT00803712	PHASE4	COMPLETED	20070360 Incident Dialysis
NCT00812123	PHASE4	COMPLETED	Calcineurin Free Immunosuppression in Renal Transplant Recipients
NCT00823303	PHASE4	COMPLETED	Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
NCT00830037	PHASE4	TERMINATED	A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
NCT00852969	PHASE4	COMPLETED	Niacin and Endothelial Function in Early CKD
NCT00858299	PHASE4	UNKNOWN	The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria
NCT00860431	PHASE4	COMPLETED	Kremezin Study Against Renal Disease Progression in Korea
NCT00882401	PHASE4	COMPLETED	Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation
NCT00889629	PHASE4	COMPLETED	Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients
NCT00892892	PHASE4	WITHDRAWN	Sympathetic Nerve Activity in Renal Failure
NCT00893425	PHASE4	COMPLETED	Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria
NCT00908310	PHASE4	COMPLETED	Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
NCT00958451	PHASE4	COMPLETED	Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients